溴隐亭联合大剂量维生素B_6治疗高泌乳血症的临床疗效观察  被引量:2

Clinical curative effect observation of bromocriptine joint high doses of vitamin B_6 in treatment of hyperpro-lactinemia

在线阅读下载全文

作  者:贺绍敏 杨娅丽 

机构地区:[1]云南省昭通市中医院,云南昭通657000

出  处:《中国当代医药》2013年第6期96-97,共2页China Modern Medicine

摘  要:目的探讨溴隐亭联合大剂量维生素B6治疗高泌乳血症的临床疗效。方法将本院收治的80例高泌乳血症患者随机分为对照组和治疗组,每组各40例,对照组给予溴隐亭治疗,治疗组在对照组的基础上给予大剂量维生素B6进行治疗,比较两组患者治疗前及治疗后1、3、6个月的血清催乳素的变化情况以及治疗6个月后的疗效。结果治疗组患者的停药率为82.5%,明显高于对照组的50.0%;治疗组患者的血清PRL恢复正常、不良反应、疗程等均明显优于对照组,两组间比较,差异有统计学意义(P<0.05)。两组患者治疗1个月后血清PRL均下降,但两者差异无统计学意义(P>0.05)。治疗3、6个月后,两组患者的血清PRL水平,差异有统计学意义(P<0.05)。结论溴隐亭联合大剂量维生素B治疗高泌乳血症可减少不良反应,缩短治疗时间。Objective To explore the clinical curative effect of bromocriptine joint high doses of vitamin B6 in treatment of hyperpro-laetinemia. Methods Eighty cases of hyperpro-laetinemia patients were randomly divided into control group and treatment group, each group of forty cases, the control group was given bromocriptine treatment, the treatment group was given large dose of Vitamin 136 on the basis of the control group, the serum prolactin changes before treatment and after treatment 1, 3, 6 months and the curative effect after treatment of 6 months were compared between the two groups. Results The withdrawal rate in the treatment group was 82.5%, which was significantly higher than that of the control group (50.0%); The serum PRL returned to normal, adverse reactions, course of treatment in treatment group were significantly superior than those of control group, the comparison between the two groups, the difference was statistically significant (P 〈 0.05). The serum PRL was decreased after 1 month treatment in two groups, but the difference was not statistically significant (P 〉 0.05). The serum PRL level after 3, 6 months treatment between the two groups, the difference was statistically significant (P 〈 0.05). Conclusion Bromocriptine joint high doses of vitamin B6 in treatment of hyperpro-lactinemia can reduce adverse reaction, shorten the treatment time.

关 键 词:溴隐亭 维生素B6 高泌乳血症 临床疗效 

分 类 号:R977.22[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象